In June 2023, Beijing VDJBio Co., LTD. announced the completion of its Series C financing, led by North Venture Capital, with follow-up investments from Hongcheng Investment, Liyuan Venture Capital, Huadian Investment, and Yiyuan Investment, and continued support from existing shareholders such as Hetang Venture Capital and Li Zaifu. This round of financing will be used for clinical trials of investigational products such as VDJ001, large-scale production of antibody drugs, and the development, production, and sales of innovative drugs in the field of autoimmune diseases.

　　Li Ziqiang, founder of Weidejie Biotechnology, said, "We are very fortunate to have received this round of financing led by North Venture Capital. We would like to express our special thanks to the new and old shareholders for their recognition of Weidejie's technology platform, management team, and R&D pipeline. Especially in the capital winter, this round of financing plays a decisive role in the company's development, laying a solid foundation for the later research and industrialization of the company's products

　　North Venture Capital's Perspective

　　Mr. He Jingwei, Chairman of North Venture Capital, stated that biopharmaceuticals are our key investment area, and there are a large number of unmet clinical needs in the field of autoimmune diseases, with a broad market space. Weidejie Biotechnology is based on antibody discovery and production platform technology, with autoimmune new biopharmaceuticals as its core. The team has deep research and development capabilities and rich experience in drug production. They have outstanding advantages in the source discovery and process development of antibody drugs, with excellent clinical data for their top products and promising industrialization in the future, contributing to the elimination of patients' pain.

　　Hongcheng Investment Opinion

　　Hongcheng Investment, as a professional investment force focused on the pharmaceutical and medical fields, is delighted to become the investor of Weidejie Biotechnology's Series C financing. We are highly optimistic about the significant advantages of the Weidejie team in the antibody discovery and production platform, as well as the highly innovative and differentiated pipeline layout in the field of autoimmune diseases and the excellent clinical data of their leading products. We look forward to Weidejie Biotechnology bringing more breakthroughs and successes with its innovative capabilities in the future.

　　Liyuan Venture Capital's viewpoint

　　Zou Yurong, a partner at Liyuan Venture Capital, stated that biopharmaceuticals are a key investment area for our company. Weidejie is an innovative biopharmaceutical enterprise that focuses on developing potential "Best in class" autoimmune disease antibody drugs with international intellectual property rights, relying on its unique, internationally leading antibody affinity enhancement platform that simulates the maturation mechanism of human antibodies. The team has rich experience in the research and industrialization of antibody new drugs, and can efficiently use funds to adopt differentiated research and development strategies, ensuring that candidate molecules have high drug potential and strong market competitiveness.     

　　Huadian Investment Perspective

　　Weidejie has excellent international vision and efficient execution ability. In targets such as IL-6R and CD80/CD86, as well as indications for rheumatoid arthritis, acute gout, etc., Weidejie's new drug pipeline has great potential. The pipeline under development belongs to the first class of new drugs. At the same time, the company has an independently developed and industry-leading antibody affinity optimization screening platform, demonstrating outstanding industry competitiveness. We look forward to helping Weidejie accelerate the process of new drug launch through this round of financing, and hope that the new drug launch can serve more domestic and foreign patients.

　　Opinion of Hetang Venture Capital

　　Qiu Qing, Managing Director of Hetang Venture Capital, stated that Hetang Venture Capital continues to have confidence in Weidejie's research and development capabilities in the field of high affinity antibodies for the treatment of autoimmune diseases. Since our initial investment, the company has made smooth progress in research and development. The core product VDJ001 has shown significant superiority over existing clinical treatment drugs in the clinical IIa phase of rare disease Castleman's disease, and preliminary clinical data in the early stages of indications for rheumatoid arthritis shows better potential than the original product. We are very optimistic about the market potential and commercial prospects of Weidejie's products.